NFKB1 and myocardial infarction: One of the most recent discoveries is the demonstration of the role of miR-21 in reducing inflammation, dysfunction, and myocardial remodelling after myocardial infarction (MI) by aiming at KBTBD7 and inhibiting the activation of signalling p38 and NF-κB, which may suggest that miR-21 may be considered a potential therapeutic target in the early stages of MI [48].